Biosion inks exclusive, global license pact with Aclaris Therapeutics on two potential first-in-class and best-in-class immunology assets: Newark, Delaware Wednesday, November 20, ...

BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired full ex-China rights to an anti-TSLP humanized mAb and ...

Don't Miss our Black Friday Offers: Roger Song’s rating is based on the promising potential of Aclaris Therapeutics’ BSI-045B, an anti-TSLP antibody that has demonstrated clinical proof of concept in ...

Jefferies upgraded Aclaris Therapeutics (ACRS) to Buy from Hold with a price target of $7, up from $2. BSI-045B is the first anti-TSLP showing clinical proof of concept in atopic dermatitis, which is ...

Aclaris partners with Biosion for anti-TSLP programs and seeks $80M funding, Keymed Biosciences signs $626M potential deal with Ouro Medicines, ReCode receives CF Foundation funding, Quell gets $10M ...

Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...

Aclaris Therapeutics (ACRS) shares surge 13% after exclusive global license deal for potential best-in-class biologics assets to bolster its pipeline.

Biosion Inc. is getting more than $40 million in cash up front from Aclaris Therapeutics Inc. for the rights to develop two antibodies. The regulatory and sales milestones could also bring Biosion ...